Frontiers in Pharmacology (Nov 2021)

Colorectal Cancer Survivors Suffering From Sensory Chemotherapy-Induced Peripheral Neuropathy Are Not a Homogenous Group: Secondary Analysis of Patients’ Profiles With Oxaliplatin-Induced Peripheral Neuropathy

  • Nicolas Kerckhove,
  • Nicolas Kerckhove,
  • Nicolas Kerckhove,
  • Marie Selvy,
  • Céline Lambert,
  • Coralie Gonneau,
  • Gabrielle Feydel,
  • Caroline Pétorin,
  • Agnès Vimal-Baguet,
  • Sergey Melnikov,
  • Sharif Kullab,
  • Mohamed Hebbar,
  • Olivier Bouché,
  • Florian Slimano,
  • Vincent Bourgeois,
  • Valérie Lebrun-Ly,
  • Frédéric Thuillier,
  • Thibault Mazard,
  • David Tavan,
  • Kheir Eddine Benmammar,
  • Brigitte Monange,
  • Mohamed Ramdani,
  • Denis Péré-Vergé,
  • Floriane Huet-Penz,
  • Ahmed Bedjaoui,
  • Florent Genty,
  • Cécile Leyronnas,
  • Jérôme Busserolles,
  • Jérôme Busserolles,
  • Sophie Trévis,
  • Vincent Pinon,
  • Denis Pezet,
  • David Balayssac,
  • David Balayssac

DOI
https://doi.org/10.3389/fphar.2021.744085
Journal volume & issue
Vol. 12

Abstract

Read online

Oxaliplatin, a pivotal drug in the management of colorectal cancer, causes chemotherapy-induced peripheral neuropathy (CIPN) in a third of cancer survivors. Based on a previous cross-sectional study assessing oxaliplatin-related sensory CIPN in colorectal cancer survivors, a secondary analysis was designed to explore the possibility that different clusters of patients may co-exist among a cohort of patients with oxaliplatin-related CIPN. Other objectives were to characterize these clusters considering CIPN severity, anxiety, depression, health-related quality of life (HRQOL), patients’ characteristics and oxaliplatin treatments. Among the 96 patients analyzed, three clusters were identified (cluster 1: 52, cluster 2: 34, and cluster 3: 10 patients). Clusters were significantly different according to CIPN severity and the proportion of neuropathic pain (cluster 1: low, cluster 2: intermediate, and cluster 3: high). Anxiety, depressive disorders and HRQOL alteration were lower in cluster 1 in comparison to clusters 2 and 3, but not different between clusters 2 and 3. This study underlines that patients with CIPN are not a homogenous group, and that CIPN severity is associated with psychological distress and a decline of HRQOL. Further studies are needed to explore the relation between clusters and CIPN management.

Keywords